ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Martin37
|
408 |
124K |
7 |
18/12/21 |
18/12/21 |
ASX - By Stock
|
408
|
124K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Martin37
|
408 |
124K |
9 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
408
|
124K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Martin37
|
408 |
124K |
28 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
408
|
124K
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Martin37
|
408 |
124K |
9 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
408
|
124K
|
9
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Martin37
|
10K |
3.0M |
11 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
10K
|
3.0M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Martin37
|
408 |
124K |
17 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
408
|
124K
|
17
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Martin37
|
10K |
3.0M |
10 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
10K
|
3.0M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Novartis Agreement
|
|
Martin37
|
850 |
252K |
21 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
850
|
252K
|
21
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Martin37
|
10K |
3.0M |
15 |
12/12/21 |
12/12/21 |
ASX - By Stock
|
10K
|
3.0M
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Greatest Benefit in Diabetics and Ischemics
|
|
Martin37
|
304 |
95K |
13 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
304
|
95K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Greatest Benefit in Diabetics and Ischemics
|
|
Martin37
|
304 |
95K |
10 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
304
|
95K
|
10
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Martin37
|
10K |
3.0M |
8 |
02/12/21 |
02/12/21 |
ASX - By Stock
|
10K
|
3.0M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Results of Meeting
|
|
Martin37
|
122 |
31K |
10 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
122
|
31K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Chairman Message to 2021 AGM
|
|
Martin37
|
54 |
20K |
7 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
54
|
20K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Chairman Message to 2021 AGM
|
|
Martin37
|
54 |
20K |
21 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
54
|
20K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Chairman Message to 2021 AGM
|
|
Martin37
|
54 |
20K |
7 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
54
|
20K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Novartis countdown
|
|
Martin37
|
373 |
112K |
17 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
373
|
112K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Martin37
|
4.7K |
1.1M |
9 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.7M |
14 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
17K
|
6.7M
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.7M |
10 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
17K
|
6.7M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
15 Days until doubt is removed
|
|
Martin37
|
953 |
291K |
26 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
953
|
291K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Martin37
|
4.7K |
1.1M |
16 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Norvatis Anniversary
|
|
Martin37
|
58 |
14K |
17 |
20/11/21 |
20/11/21 |
ASX - By Stock
|
58
|
14K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Martin37
|
4.7K |
1.1M |
16 |
20/11/21 |
20/11/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Martin37
|
1.0K |
279K |
19 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
1.0K
|
279K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Martin37
|
1.0K |
279K |
46 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
1.0K
|
279K
|
46
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Martin37
|
1.0K |
279K |
46 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
1.0K
|
279K
|
46
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Martin37
|
1.0K |
279K |
45 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
1.0K
|
279K
|
45
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Martin37
|
1.0K |
279K |
13 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
1.0K
|
279K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: CHF Late Breaker Presentation at American Heart Association
|
|
Martin37
|
350 |
125K |
8 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
350
|
125K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: CHF Late Breaker Presentation at American Heart Association
|
|
Martin37
|
350 |
125K |
36 |
13/11/21 |
13/11/21 |
ASX - By Stock
|
350
|
125K
|
36
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.7M |
20 |
13/11/21 |
13/11/21 |
ASX - By Stock
|
17K
|
6.7M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.7M |
32 |
13/11/21 |
13/11/21 |
ASX - By Stock
|
17K
|
6.7M
|
32
|
|
ASX - By Stock
|
MSB |
Re:
Novartis countdown
|
|
Martin37
|
373 |
112K |
24 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
373
|
112K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Novartis countdown
|
|
Martin37
|
373 |
112K |
17 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
373
|
112K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
15 Days until doubt is removed
|
|
Martin37
|
953 |
291K |
10 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
953
|
291K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
15 Days until doubt is removed
|
|
Martin37
|
953 |
291K |
0 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
953
|
291K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
Martin37
|
173 |
47K |
2 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
173
|
47K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
Martin37
|
173 |
47K |
0 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
173
|
47K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Annual Report to Shareholders
|
|
Martin37
|
84 |
26K |
12 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
84
|
26K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Annual Report to Shareholders
|
|
Martin37
|
84 |
26K |
13 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
84
|
26K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
Martin37
|
173 |
47K |
9 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
173
|
47K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
Martin37
|
173 |
47K |
14 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
173
|
47K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.7M |
5 |
26/10/21 |
26/10/21 |
ASX - By Stock
|
17K
|
6.7M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Where is Novartis?
|
|
Martin37
|
1.5K |
415K |
2 |
25/10/21 |
25/10/21 |
ASX - By Stock
|
1.5K
|
415K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Where is Novartis?
|
|
Martin37
|
1.5K |
415K |
3 |
25/10/21 |
25/10/21 |
ASX - By Stock
|
1.5K
|
415K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Where is Novartis?
|
|
Martin37
|
1.5K |
415K |
9 |
24/10/21 |
24/10/21 |
ASX - By Stock
|
1.5K
|
415K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Where is Novartis?
|
|
Martin37
|
1.5K |
415K |
8 |
23/10/21 |
23/10/21 |
ASX - By Stock
|
1.5K
|
415K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Where is Novartis?
|
|
Martin37
|
1.5K |
415K |
13 |
23/10/21 |
23/10/21 |
ASX - By Stock
|
1.5K
|
415K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.7M |
7 |
22/10/21 |
22/10/21 |
ASX - By Stock
|
17K
|
6.7M
|
7
|
|